Generate Biomedicines · Company profile
Generate Biomedicines · 美国 · AI, models, and data
Registered focus: 生成式蛋白设计、生物药. Focus is directory metadata; inspect the sources and project evidence below to assess specific capabilities.
Public reviewed developments
There are currently no matching public reviewed events.
Collaboration, licensing, and acquisition timeline
No collaboration, licensing, or acquisition nodes appear in the developments shown here. This does not establish that the company has never had such activity.
These are drawn from the latest 0 reviewed developments. A collaboration, model performance, experimental results, and clinical progress each require their own evidence.
Public source records
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
Generate Biomedicines official news-release RSS · Indexed industry source record · Source published: Thu Oct 01 2026 11:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)
Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical trial underway at Roswel
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering
Generate Biomedicines official news-release RSS · Indexed industry source record · Source published: Thu Feb 26 2026 23:11:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)
SOMERVILLE, Mass., February 26, 2026 — Generate Biomedicines, Inc. (Nasdaq: GENB) (“Generate”), a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development, t
Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI
Generate Biomedicines official news-release RSS · Indexed industry source record · Source published: Mon Dec 01 2025 10:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)
SOLAIRIA‑1 and SOLAIRIA‑2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies These are the first global Phase 3 studies of a long-a
Generate:Biomedicines to Present Phase 1 Results for AI-Engineered GB-0895 in Asthma at the European Respiratory Society International Congress
Generate Biomedicines official news-release RSS · Indexed industry source record · Source published: Thu Sep 25 2025 11:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)
GB-0895, a next-generation, ultra-high affinity anti-TSLP monoclonal antibody, demonstrated prolonged half-life and sustained pharmacology in asthma patients GB-0895 is optimized for a single subcutaneous injection every
Verified official and subscription sources
- Generate Biomedicines official news-release RSS · Collection enabled · Last successful collection Fri Oct 09 2026 08:07:53 GMT+0000 (Coordinated Universal Time)
Source verification and ongoing collection are shown separately. Indexed source records do not automatically become reviewed events.
Reader guides: from sources to conclusions
Compare models by task and follow collaborations through evidence. Each guide includes original sources and a review date.
How should we compare virtual cells, AI models, and companies?
Compare single-cell models, structure prediction, and protein design by inputs, outputs, tasks, and validation conditions. Distinguish model papers from company capabilities.
Reader guide · updated 2026-10-08
AI drug discovery collaboration timelines: from announcements to evidence
Use real official announcements to distinguish partners, upfront payments, conditional milestones, and R&D progress, and build a traceable collaboration timeline.
Reader guide · updated 2026-10-08
How to read weekly AI drug discovery updates: companies, research, and coverage gaps
Build a weekly reading routine, distinguish announcements, papers, and clinical results, and understand this site’s weekly indexing window, denominators, and source coverage.
Reader guide · updated 2026-10-08